Welcome to our dedicated page for THERIVA BIOLOGICS news (Ticker: TOVX), a resource for investors and traders seeking the latest updates and insights on THERIVA BIOLOGICS stock.
Theriva Biologics, Inc. (NYSE American: TOVX) is a clinical-stage company whose news flow centers on the development of therapeutics for cancer and related diseases. The company regularly issues updates on its lead oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec), including clinical trial results, regulatory interactions, and presentations at major medical congresses.
Investors following TOVX news can expect coverage of data from the VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma, where Theriva has reported improved overall survival, progression free survival, and duration of response for patients treated with VCN-01 plus gemcitabine/nab-paclitaxel compared with standard-of-care alone. News also highlights regulatory milestones such as scientific advice from the European Medicines Agency’s Committee for Medicinal Products for Human Use on the design of a proposed Phase 3 trial, and company plans to discuss pivotal trial protocols with regulators.
Theriva’s releases also describe progress in retinoblastoma, including Phase 1 safety and clinical outcome data for intravitreal VCN-01 in refractory pediatric patients, as well as preclinical developments from the VCN-X discovery program, such as VCN-12. Beyond oncology, news items cover SYN-004 (ribaxamase) data in allogeneic hematopoietic cell transplant recipients and its potential role in protecting the gut microbiome and reducing acute graft-versus-host disease.
Additional TOVX news includes quarterly operational and financial updates, public offerings and warrant transactions, at-the-market equity programs, and proxy-related matters tied to share issuance approvals. This page aggregates these disclosures so readers can review Theriva’s clinical, regulatory, and financing developments in one place and track how its pipeline and capital strategy evolve over time.
Summary not available.
Summary not available.
Summary not available.
Theriva Biologics (TOVX) announced the presentation of interim blinded safety and pharmacokinetic data from its ongoing Phase 1b/2a trial of SYN-004 (ribaxamase) at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The trial aims to prevent acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. Results will be presented on April 17, 2023, by Dr. Erik R. Dubberke. The trial evaluates safety and absorption of SYN-004 in patients undergoing treatment with IV antibiotics, which can negatively impact the gut microbiome. Prior trials have indicated SYN-004's efficacy in protecting gut health during antibiotic use, crucial for HCT patients. This data could also impact regulatory pathways and future commercial viability.
Theriva Biologics (TOVX) announced the dosing of the first patients in significant clinical trials for its lead drug VCN-01, targeting pancreatic ductal adenocarcinoma and brain tumors. The company presented positive data for SYN-004 at the 2023 Tandem Meetings, indicating good safety profiles. Financially, Theriva reported $41.8 million in cash as of December 31, 2022, ensuring operations into Q3 2024. However, R&D expenses increased 50% to $11.7 million, and general and administrative costs rose 50.8% to $9.9 million. The firm aims to leverage its oncology platform and expand its clinical development programs.
Theriva Biologics (TOVX) plans to host a conference call on March 30, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and provide a corporate update. This call was rescheduled from its original date of March 27, 2023. Investors can participate via telephone or access a live and archived webcast through the company’s website. Theriva Biologics focuses on developing therapeutics for cancer and related diseases, with lead candidates including VCN-01 and SYN-004. The conference call aims to offer insights into the company’s financial performance and strategic direction.
Theriva Biologics (NYSE American: TOVX) announced a conference call on March 27, 2023, at 8:30 a.m. ET to discuss its financial results for Q4 and the full year ending December 31, 2022, along with corporate updates. The company is focused on developing therapeutics to treat cancer and related diseases, emphasizing its lead candidates: VCN-01, SYN-004, and SYN-020. These candidates target tumor cell death, prevent microbiome damage, and aim to treat gastrointestinal and systemic diseases, respectively. Investors can join the live call or access it later via the company's website.
Theriva Biologics (TOVX) reported positive safety and pharmacokinetic data from its Phase 1b/2a trial of SYN-004 (ribaxamase) at the 2023 Tandem Meetings. The ongoing trial focuses on HCT patients to prevent acute graft-versus-host disease. Preliminary findings show that SYN-004 is well-tolerated, with no serious adverse events linked to the drug. The trial is evaluating different beta-lactam antibiotics and aims to enroll up to 36 participants. The company plans further studies to assess SYN-004's potential benefits for patients with hematologic cancers.
Theriva Biologics (NYSE American: TOVX) announced its participation in the B. Riley Securities 3rd Annual Oncology Conference, scheduled for January 18-19, 2023. The Company will provide a corporate update and hold one-on-one investor meetings. The presentation is set for January 19, 2023, at 1:30 PM ET. Theriva specializes in developing therapeutics for cancer and related diseases, focusing on high unmet medical needs. Their key candidates include VCN-01, SYN-004, and SYN-020, aimed at enhancing cancer treatment efficacy and improving patient outcomes. For more details, visit their website.
Theriva Biologics (NYSE American: TOVX) announced the initiation of its Phase 2b trial, VIRAGE, for the treatment of newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). The first patient has been dosed in Spain, with a total enrollment of 92 adults planned across the US, Spain, and Germany. The trial will evaluate the safety and efficacy of VCN-01 combined with standard chemotherapy (gemcitabine/nab-paclitaxel). Primary endpoints include overall survival and safety, with additional metrics assessing progression-free survival and immune response. This trial represents a vital step towards improving treatment for patients with high unmet needs in oncology.
FAQ
What is the current stock price of THERIVA BIOLOGICS (TOVX)?
What is the market cap of THERIVA BIOLOGICS (TOVX)?
